EMA’s Revised Guide On Additional Risk Minimization ‘Overly Detailed’
EU Pharma Association Pushes For Greater Use Of Digital Formats
Executive Summary: The European pharma industry federation believes the advice provided in the updated draft EU guideline on additional risk minimization measures is far too detailed, resulting in a lack of focus, information overlap and confusion.
You may also be interested in...
Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The Association of Contract Research Organizations’ revised toolkit on decentralized trials explains how to deal with data quality and integrity.